US vaccine maker Novavax stated on Monday that new information from Novavax’s ongoing analysis on its up to date XBB.1.5 Covid-19 vaccine in individuals who beforehand acquired an mRNA vaccine confirmed sturdy neutralizing antibody titers for the XBB.1.5 subvariant in addition to for the at present circulating JN.1 subvariant.
The information additionally confirmed that the vaccine’s security and reactogenicity profile was according to its prototype vaccine (NVX-CoV2373).
Source: www.anews.com.tr